Drug Trial Radar · NCT05630807
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
981
Actual
Start
Dec 7, 2022
Primary completion
Nov 11, 2025
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos(t)ide analogue (NA) treatment for 24 weeks. c) NA cessation stage OR Continue NA for 24 weeks. d) Durability of response and follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to \[≥\] 100 international unit per milliliter \[IU/mL\] to less than or equal \[≤\]1000 IU/mL or greater than \[\>\] 1000 IU/mL to ≤3000 IU/mL) at screening. The total duration of the study, including screening (up to 60 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 104 weeks at maximum for each participant.
Conditions
- Chronic Hepatitis B
- Hepatitis B, Chronic
Interventions
BepirovirsenDrug
Bepirovirsen will be administered.
PlaceboOther
Matching placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving functional cure (FC) with baseline HBsAg ≤3000 IU/mLTime frame: Up to 72 weeks
Locations
177 sites in 26 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Davis, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palo Alto, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Argentina
GSK Investigational Site
Derqui Pilar, Argentina
GSK Investigational Site
Rosario, Argentina
GSK Investigational Site
Aracaju, Brazil
GSK Investigational Site
Campinas, Brazil
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Manaus, Brazil
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Santa Maria, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vila Mariana, Brazil
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Veliko Tarnovo, Bulgaria
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint-Jérôme, Quebec, Canada
GSK Investigational Site
Beijing, China
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.